What 18 Analyst Ratings Have To Say About Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:
Last 30 Days
1 Month Ago
2 Months Ago
Morgan Stanley Maintains Overweight on Biogen, Lowers Price Target to $453
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Overweight and lowers the price target from $455 to $453.
AMD And Biogen Lead The QQQ Lower Thursday
U.S. indices were trading lower Thursday as investors weigh Fed Chair Powell’s comments on inflation to the Senate banking panel.
Biogen Shares Are Trading Lower As Cleveland Clinic, Mount Sinai Decline To Aduhelm Administration
A pair of large hospitals have declined to administer Biogen Inc’s (NASDAQ:BIIB) Alzheimer’s treatment Aduhelm, Wall Street Journal reported. The Cleveland…
Why Shares Of Biogen Are Trading Lower Today
Biogen (NASDAQ: BIIB) shares are trading lower after Cleveland Clinic said it would not administer the company's Aduhelm Alzheimer's medication, which has added to controversy surrounding the drug.
UPDATE: New York Time Wednesday Reported Cleveland Clinic, Mount Sinai Won’t Administer Biogen’s Aduhelm To Patients
https://www.nytimes.com/2021/07/14/health/cleveland-clinic-aduhelm.html
Biogen’s Alzheimer’s Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News
Acting FDA Commissioner Janet Woodcock pushed back against media questions about the agency’s controversial approval of Alzheimer’s treatment,…
Benzinga Pro’s Top 5 Stocks To Watch For Monday, Jul. 12, 2021 (Earnings Season Edition): DAL, MS, BIIB, TWTR, NUE
Today's 5 Stock Ideas (Earnings Season Edition)
Delta Air (DAL) - To issue Q2 earnings on Wednesday, Jul. 14 before market open.
Morgan Stanley (MS) - Will report quarterly earnings before market open
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow.